Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin

Atherosclerosis

Volumn 143, Issue 2, 1999, Pages 415-425

  Lagrost, Laurent ^a   Athias, Anne ^a   Lemort, Nicole ^b   Richard, Jean Louis ^b   Desrumaux, Catherine ^a   Châtenet Duchêne, Liliane ^c   Courtois, Mercedes ^c   Farnier, Michel ^d   Jacotot, Bernard ^b   Braschi, Sylvie ^b   Gambert, Philippe ^a  

^a INSERM   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c SANOFI   (France)

^d Le Point Médical   (France)

Author keywords

Cholesteryl ester transfer protein; HMG CoA reductase inhibitor; Hyperlipidemia; Phospholipid transfer protein

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; LOW DENSITY LIPOPROTEIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPID METABOLISM; LIPID TRANSPORT; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032894351     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00299-8     Document Type: Article

References (44)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
2. Bagdade J.D., Lane J.T., Stone N., Ritter M.C., Subbaiah P.V. Persistent abnormalities in lipoprotein composition and cholesteryl ester transfer following lovastatin treatment. J Lipid Res. 31:1990;1263-1269.
3. Nakandakare E., Garcia R.C., Rocha J.C., Sperotto G., Oliveira H.C.F., Quintao E.C.R. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins. Atherosclerosis. 85:1990;211-217.
4. Johansson J., Mölgaard J., Olsson A.G. Plasma high density lipoprotein particle size alteration by simvastatin treatment in patients with hypercholesterolemia. Atherosclerosis. 91:1991;175-184.
5. Gaw A., Packard C.J., Murray E.F., Lindsay G.M., Griffin B.A., Caslake M.J., Vallance B.D., Lorimer A.R., Shepherd J. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler Thromb. 13:1993;170-189.
6. Homma Y., Ozawa H., Kobayashi T., Yamaguchi H., Sakane H., Nakamura H. Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia. Atherosclerosis. 114:1995;223-234.
7. Bredie S.J.H., de Bruin T.W.A., Demacker P.N.M., Kastelein J.J.P., Stalenhoef A.F.H. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoproteinB-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol. 75:1995;348-353.
8. Kontopoulos A.G., Athyros V.G., Papageorgiou A.A., Hatzikonstandinou H.A., Mayroudi M.C., Boudoulas H. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coronary Artery Dis. 7:1996;843-850.
9. Vega G.L., Krauss R.M., Grundy S.M. Pravastatin therapy in primary moderate hypercholesterolemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J Int Med. 227:1990;81-94.
10. Kagami A., Ishikawa T., Tada N., Sakamoto T., Mochizuki K., Nagano M., Morigushi E.H., Manabe M. Effects of probucol and pravastatin on plasma lipids, activities of postheparin lipoprotein lipase, and lecithin cholesterol acyltransferase and apo A-I containing lipoproteins with and without apo A-II in patients with moderate hypercholesterolemia. Clin Biochem. 26:1993;101-107.
11. Cheung M.C., Austin M.A., Moulin P., Wolf A.C., Cryer D., Knopp R.H. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis. 102:1993;107-119.
12. Zambon S., Cortella A., Sartore G., Baldo-Enzi G., Manzato E., Crepaldi G. Pravastatin treatment in combined hyperlipidemia. Effect on plasma lipoprotein levels and size. Eur J Clin Pharmacol. 46:1994;221-224.
13. Franceschini G., Cassinotti M., Vecchio G., Gianfranceschi G., Pazzucconi F., Murakami T., Sirtori M., D'Acquarica A.L., Sirtori C.R. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler Thromb. 14:1994;1569-1575.
14. Guérin M., Dolphin P.J., Talussot C., Gardette J., Berthézène F., Chapman M.J. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 15:1995;1359-1368.
15. 2b subclass protein concentration after pravastatin treatment in patients with hypercholesterolemia. Curr Ther Res. 57:1996;336-342.
16. Deckelbaum R.J., Eisenberg S., Oschry Y., Butbul E., Sharon I., Olivecrona T. Reversible modification of human plasma low density lipoproteins towards triglyceride-rich precursors: a mechanism for losing excess cholesterol esters. J Biol Chem. 257:1982;6509-6517.
17. Lagrost L., Gambert P., Lallemant C. Combined effects of lipid transfers and lipolysis on gradient gel patterns of human plasma LDL. Arterioscler Thromb. 14:1994;1327-1336.
18. Barrans A., Collet X., Barbaras R., Jaspard B., Manent J., Vieu C., Chap H., Perret B. Hepatic lipase induces the formation of pre-β1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases. J Biol Chem. 269:1994;11572-11577.
19. Clay M.A., Newnham H.H., Forte T.M., Barter P.J. Cholesteryl ester transfer protein and hepatic lipase activity promote shedding of apo A-I from HDL and subsequent formation of discoidal HDL. Biochim Biophys Acta. 1124:1992;52-58.
20. Tu A.-Y., Nishida H.I., Nishida T. High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. J Biol Chem. 268:1993;23098-23105.
21. Jauhiainen M., Metso J., Pahlman R., Blomqvist S., van Tol A., Enholm C. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem. 268:1993;4032-4036.
22. von Eckardstein A., Jauhiainen M., Huang Y., Metso J., Langer C., Pussinen P., Wu S., Ehnholm C., Assman G. Phospholipid transfer protein mediated conversion of high density lipoproteins generates preβ1-HDL. Biochim Biophys Acta. 1301:1996;255-262.
23. Lagrost L. Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies. Biochim Biophys Acta. 1215:1994;209-236.
24. Hibino T., Sakuma N., Sato T., Yoneyama A., Fujinami T. Decrease in plasma cholesteryl-ester transfer protein activity with simvastatin treatment in patients with type IIa hypercholesterolemia. Curr Ther Res. 57:1996;42-47.
25. Chapman M.J., Goldstein S., Lagrange D., Laplaud P.M. A density gradient ultracentrifugation procedure for the isolation of the major lipoprotein classes from human serum. J Lipid Res. 22:1981;339-358.
26. Redgrave T.G., Roberts D.C.K., West C.E. Separation of plasma lipoproteins by density gradient ultracentrifugation. Anal Biochem. 65:1975;42-49.
27. Blanche P.J., Gong E.L., Forte T.M., Nichols A.V. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta. 665:1981;408-419.
28. Cheung M.C., Brown B.G., Wolf A.C., Albers J.J. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res. 32:1991;383-394.
29. Lagrost L., Athias A., Herbeth B., Guyard-Dangremont V., Artur Y., Paille F., Gambert P., Lallemant C. Opposite effects of cholesteryl ester transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins. Physiological relevance in alcoholic patients. J Biol Chem. 271:1996;19058-19065.
30. Guyard-Dangremont V., Lagrost L., Gambert P., Lallemant C. Competitive enzyme-linked immunosorbent assay of the human cholesteryl ester transfer protein (CETP). Clin Chim Acta. 231:1994;147-160.
31. Lagrost L., Gandjini H., Athias A., Guyard-Dangremont V., Lallemant C., Gambert P. Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects. Arterioscler Thromb. 13:1993;815-825.
32. Braschi S., Lagrost L., Florentin E., Martin C., Athias A., Gambert P., Krempf M., Lallemant C., Jacotot B. Increased cholesteryl ester transfer activity in plasma from analbuminemic patients. Arterioscler Thromb Vasc Biol. 16:1996;441-449.
33. Friedewald T.W., Levy R.I., Frederickson D.S. Estimation of the concentration of the low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
34. Vega G.L., Grundy S.M. Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia. J Int Med. 230:1991;341-349.
35. Nishiwaki M., Ishikawa T., Homma Y., Tada N., Kagami A., Ohshima K., Ito T., Tomiyasu K., Shige H., Miyajima E., Nakamura H. Effects of pravastatin on plasma lipids, apolipoproteins, Lp(a), remnant-like particle, cholesteryl ester transfer protein, and lecithin:cholesterol acyltransferase; a 12-month study. Nutr Metab Cardiovasc Dis. 4:1994;10-15.
36. Ahnadi C.-E., Berthézène F., Ponsin G. Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. Atherosclerosis. 99:1993;219-228.
37. McNamara J.R., Jenner J.L., Li Z., Wilson P.W.F., Schaefer E.J. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb. 12:1992;1284-1290.
38. Bruckert E., Dejager S., Chapman M.J. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis. 100:1993;91-102.
39. Guérin M., Bruckert E., Dolphin P.J., Turpin G., Chapman M.J. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 16:1996;763-772.
40. McPherson R., Lau P., Kussie P., Barrett H., Tall A.R. Plasma kinetics of cholesteryl ester transfer protein in the rabbit. Effects of dietary cholesterol. Arterioscler Thromb Vasc Biol. 17:1997;203-210.
41. Mann C.J., Yen F.T., Grant A.M., Bihain B.E. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest. 88:1991;2059-2066.
42. Jiang X.C., Masucci-Magoulas L., Mar J., Lin M., Walsh A., Breslow J.L., Tall A.R. Down-regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein. Mechanism to explain accumulation of lipoprotein B particles. J Biol Chem. 268:1993;27406-27412.
43. Oliveira H.C.F., Chouinard R.A., Agellon L.B., Bruce C., Ma L., Walsh A., Breslow J.L., Tall A.R. Human cholesteryl ester transfer protein gene proximal promoter contains dietary cholesterol positive responsive elements and mediates expression in small intestine and periphery while predominant liver and spleen expression is controlled by 5'-distal sequences. Cis-acting sequences mapped in transgenic mice. J Biol Chem. 271:1996;31831-31838.
44. Masucci-Magoulas L., Plump A., Jiang X.C., Walsh A., Breslow J.L., Tall A.R. Profound induction of hepatic cholesteryl ester transfer protein transgene expression in apolipoprotein E and low density lipoprotein receptor gene knockout mice. A novel mechanism signals changes in plasma cholesterol levels. J Clin Invest. 97:1996;154-161.